International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 2 , Pages 351-357 , 1 June 2008

Acute Toxicity in Definitive Versus Postprostatectomy Image-Guided Radiotherapy for Prostate Cancer

  • Jonathan C. Cheng, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
    • Department of Radiation Oncology, University of California at Irvine Medical Center, Orange, CA
    • ,
  • Timothy E. Schultheiss, Ph.D.

      Affiliations

    • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
    • Corresponding Author InformationReprint requests to: Timothy E. Schultheiss, Ph.D., Department of Radiation Physics, City of Hope Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010-3000. Tel: (626) 301-8247; Fax: (626) 930-5334
    • ,
  • Khanh H. Nguyen, M.D.

      Affiliations

    • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
    • ,
  • Jeffrey Y.C. Wong, M.D.

      Affiliations

    • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA

Received 24 August 2007 ,Revised 13 September 2007 ,Accepted 27 September 2007.

References 

  1. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33
  2. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225–2229
  3. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  4. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47:103–113
  5. Kupelian PA, Reddy CA, Carlson TP, et al. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: Absolute or relative rectal volume?. Cancer J. 2002;8:62–66
  6. O'Brien PC, Franklin CI, Poulsen MG, et al. Trans-Tasman Radiation Oncology Group Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: Longer term follow-up of a phase III trial. Int J Radiat Oncol Biol Phys. 2002;54:442–449
  7. De Meerleer G, Vakaet L, Meersschout S, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys. 2004;60:777–787
  8. Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:3–11
  9. Yeoh EE, Botten R, Russo A, et al. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys. 2000;47:915–924
  10. Sharma R, Chuba PJ, Duclos M, et al. Differences in dosimetry and toxicity between definitive and postprostatectomy radiation therapy. Radiology. 1997;204:211–212
  11. Teh BS, Mai WY, Augspurger ME, et al. Intensity modulated radiation therapy (IMRT) following prostatectomy: More favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:465–472
  12. Zelefsky MJ, Aschkenasy E, Kelsen S, et al. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39:327–333
  13. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In:  Tannenbaum M editors. Urologic pathology: The prostate. Philadelphia: Lea and Febiger; 1977;p. 171–197
  14. Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 2000;46:391–402
  15. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  16. Vavassori V, Fiorino C, Rancati T, et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007;67:1401–1410
  17. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys. 2005;62:706–713
  18. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–1034
  19. Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;63:1142–1152
  20. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85:2460–2468
  21. Hanks GE, Schultheiss TE, Hunt MA, et al. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1995;31:25–29
  22. Teh BS, Mai WY, Uhl BM, et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: Acute toxicity and dose–volume analysis. Int J Radiat Oncol Biol Phys. 2001;49:705–712
  23. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  24. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002;54:1036–1046
  25. Nuyttens JJ, Milito S, Rust PF, et al. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol. 2002;64:209–214
  26. Koper PC, Stroom JC, van Putten WL, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomized study. Int J Radiat Oncol Biol Phys. 1999;43:727–734
  27. Lebesque JV, Bruce AM, Kroes AP, et al. Variation in volumes, dose–volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys. 1995;33:1109–1119
  28. Leibel SA, Heimann R, Kutcher GJ, et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: Preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys. 1994;28:55–65

 These data were presented at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), October 28–November 1, 2007, Los Angeles, CA.

 Conflict of interest: none.

PII: S0360-3016(07)04367-2

doi: 10.1016/j.ijrobp.2007.09.043

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 2 , Pages 351-357 , 1 June 2008

Article Tools

* Image Usage & Resolution